Do analysts recommend NCYT or EKF?

EKF Diagnostics has a consensus price target of GBX 35, indicating a potential upside of 42.28%. Given EKF Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe EKF Diagnostics is more favorable than Novacyt. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novacyt 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 EKF Diagnostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has better earnings and valuation, NCYT or EKF?

EKF Diagnostics has higher revenue and earnings than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novacyt £20.03M 1.34 -£36.80M -£32.00 N/A EKF Diagnostics £51.35M 2.05 £4.68M £0.47 52.34

Is NCYT or EKF more profitable?

EKF Diagnostics has a net margin of 4.86% compared to Novacyt's net margin of -103.08%. EKF Diagnostics' return on equity of 3.58% beat Novacyt's return on equity. Company Net Margins Return on Equity Return on Assets Novacyt -103.08% -96.44% -27.98% EKF Diagnostics 4.86% 3.58% 5.27%

Which has higher valuation & earnings, SPEC or NCYT?

INSPECS Group has higher revenue and earnings than Novacyt. INSPECS Group is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio INSPECS Group £193.23M 0.53 -£4.11M -£9.40 N/A Novacyt £20.03M 1.34 -£36.80M -£32.00 N/A

Is SPEC or NCYT more profitable?

INSPECS Group has a net margin of -0.52% compared to Novacyt's net margin of -103.08%. INSPECS Group's return on equity of -1.19% beat Novacyt's return on equity. Company Net Margins Return on Equity Return on Assets INSPECS Group -0.52% -1.19% 0.45% Novacyt -103.08% -96.44% -27.98%

Does the media prefer NCYT or CREO?

In the previous week, Creo Medical Group had 1 more articles in the media than Novacyt. MarketBeat recorded 4 mentions for Creo Medical Group and 3 mentions for Novacyt. Creo Medical Group's average media sentiment score of 0.46 beat Novacyt's score of -0.37 indicating that Creo Medical Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novacyt 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Creo Medical Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BVC or NCYT?

In the previous week, Novacyt had 2 more articles in the media than BATM Advanced Communications. MarketBeat recorded 3 mentions for Novacyt and 1 mentions for BATM Advanced Communications. BATM Advanced Communications' average media sentiment score of 0.66 beat Novacyt's score of -0.37 indicating that BATM Advanced Communications is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BATM Advanced Communications 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novacyt 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Novacyt (NCYT) Competitors

GBX 37 -3.00 (-7.50%)

As of 10/2/2026 12:00 PM Eastern

Compare

NCYT vs. EKF, SPEC, CREO, IUG, and BVC

Should you buy Novacyt stock or one of its competitors? Novacyt's main competitors and comparable companies include EKF Diagnostics (EKF), INSPECS Group (SPEC), Creo Medical Group (CREO), Intelligent Ultrasound Group (IUG), and BATM Advanced Communications (BVC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Novacyt compare to EKF Diagnostics?

Novacyt (LON:NCYT) and EKF Diagnostics (LON:EKF) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

EKF Diagnostics has higher revenue and earnings than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novacyt	£20.03M	1.34	-£36.80M	-£32.00	N/A
EKF Diagnostics	£51.35M	2.05	£4.68M	£0.47	52.34

Novacyt has a beta of 1.112, indicating that its share price is 11% more volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.499, indicating that its share price is 50% less volatile than the broader market.

EKF Diagnostics has a net margin of 4.86% compared to Novacyt's net margin of -103.08%. EKF Diagnostics' return on equity of 3.58% beat Novacyt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novacyt	-103.08%	-96.44%	-27.98%
EKF Diagnostics	4.86%	3.58%	5.27%

EKF Diagnostics has a consensus price target of GBX 35, indicating a potential upside of 42.28%. Given EKF Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe EKF Diagnostics is more favorable than Novacyt.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novacyt	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
EKF Diagnostics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Novacyt had 3 more articles in the media than EKF Diagnostics. MarketBeat recorded 3 mentions for Novacyt and 0 mentions for EKF Diagnostics. EKF Diagnostics' average media sentiment score of 0.00 beat Novacyt's score of -0.37 indicating that EKF Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Novacyt	Neutral
EKF Diagnostics	Neutral

10.7% of Novacyt shares are held by institutional investors. Comparatively, 22.2% of EKF Diagnostics shares are held by institutional investors. 0.4% of Novacyt shares are held by insiders. Comparatively, 40.2% of EKF Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

EKF Diagnostics beats Novacyt on 14 of the 16 factors compared between the two stocks.

How does Novacyt compare to INSPECS Group?

INSPECS Group (LON:SPEC) and Novacyt (LON:NCYT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

INSPECS Group has higher revenue and earnings than Novacyt. INSPECS Group is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INSPECS Group	£193.23M	0.53	-£4.11M	-£9.40	N/A
Novacyt	£20.03M	1.34	-£36.80M	-£32.00	N/A

INSPECS Group has a net margin of -0.52% compared to Novacyt's net margin of -103.08%. INSPECS Group's return on equity of -1.19% beat Novacyt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INSPECS Group	-0.52%	-1.19%	0.45%
Novacyt	-103.08%	-96.44%	-27.98%

0.2% of INSPECS Group shares are owned by institutional investors. Comparatively, 10.7% of Novacyt shares are owned by institutional investors. 19.6% of INSPECS Group shares are owned by company insiders. Comparatively, 0.4% of Novacyt shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Novacyt had 3 more articles in the media than INSPECS Group. MarketBeat recorded 3 mentions for Novacyt and 0 mentions for INSPECS Group. INSPECS Group's average media sentiment score of 0.00 beat Novacyt's score of -0.37 indicating that INSPECS Group is being referred to more favorably in the media.

Company	Overall Sentiment
INSPECS Group	Neutral
Novacyt	Neutral

INSPECS Group has a beta of 1.603, meaning that its stock price is 60% more volatile than the broader market. Comparatively, Novacyt has a beta of 1.112, meaning that its stock price is 11% more volatile than the broader market.

Summary

INSPECS Group beats Novacyt on 9 of the 13 factors compared between the two stocks.

How does Novacyt compare to Creo Medical Group?

Novacyt (LON:NCYT) and Creo Medical Group (LON:CREO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Novacyt has a net margin of -103.08% compared to Creo Medical Group's net margin of -268.57%. Creo Medical Group's return on equity of -38.29% beat Novacyt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novacyt	-103.08%	-96.44%	-27.98%
Creo Medical Group	-268.57%	-38.29%	-20.09%

In the previous week, Creo Medical Group had 1 more articles in the media than Novacyt. MarketBeat recorded 4 mentions for Creo Medical Group and 3 mentions for Novacyt. Creo Medical Group's average media sentiment score of 0.46 beat Novacyt's score of -0.37 indicating that Creo Medical Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novacyt	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Creo Medical Group	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

10.7% of Novacyt shares are held by institutional investors. Comparatively, 44.1% of Creo Medical Group shares are held by institutional investors. 0.4% of Novacyt shares are held by insiders. Comparatively, 7.0% of Creo Medical Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Novacyt has a beta of 1.112, indicating that its share price is 11% more volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.563854, indicating that its share price is 56% more volatile than the broader market.

Creo Medical Group has lower revenue, but higher earnings than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novacyt	£20.03M	1.34	-£36.80M	-£32.00	N/A
Creo Medical Group	£7M	6.71	-£25.04M	£1.00	9.67

Summary

Creo Medical Group beats Novacyt on 11 of the 13 factors compared between the two stocks.

How does Novacyt compare to Intelligent Ultrasound Group?

Intelligent Ultrasound Group (LON:IUG) and Novacyt (LON:NCYT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, Novacyt had 3 more articles in the media than Intelligent Ultrasound Group. MarketBeat recorded 3 mentions for Novacyt and 0 mentions for Intelligent Ultrasound Group. Intelligent Ultrasound Group's average media sentiment score of 0.00 beat Novacyt's score of -0.37 indicating that Intelligent Ultrasound Group is being referred to more favorably in the media.

Company	Overall Sentiment
Intelligent Ultrasound Group	Neutral
Novacyt	Neutral

Intelligent Ultrasound Group has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Novacyt has a beta of 1.112, suggesting that its stock price is 11% more volatile than the broader market.

Intelligent Ultrasound Group has a net margin of -23.11% compared to Novacyt's net margin of -103.08%. Intelligent Ultrasound Group's return on equity of -23.58% beat Novacyt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intelligent Ultrasound Group	-23.11%	-23.58%	-13.51%
Novacyt	-103.08%	-96.44%	-27.98%

75.5% of Intelligent Ultrasound Group shares are owned by institutional investors. Comparatively, 10.7% of Novacyt shares are owned by institutional investors. 12.8% of Intelligent Ultrasound Group shares are owned by insiders. Comparatively, 0.4% of Novacyt shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Intelligent Ultrasound Group has higher earnings, but lower revenue than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than Intelligent Ultrasound Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intelligent Ultrasound Group	£6.57M	0.00	-£2.27M	-£0.68	N/A
Novacyt	£20.03M	1.34	-£36.80M	-£32.00	N/A

Summary

Intelligent Ultrasound Group beats Novacyt on 8 of the 12 factors compared between the two stocks.

How does Novacyt compare to BATM Advanced Communications?

BATM Advanced Communications (LON:BVC) and Novacyt (LON:NCYT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

In the previous week, Novacyt had 2 more articles in the media than BATM Advanced Communications. MarketBeat recorded 3 mentions for Novacyt and 1 mentions for BATM Advanced Communications. BATM Advanced Communications' average media sentiment score of 0.66 beat Novacyt's score of -0.37 indicating that BATM Advanced Communications is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BATM Advanced Communications	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novacyt	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BATM Advanced Communications has higher revenue and earnings than Novacyt. BATM Advanced Communications is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BATM Advanced Communications	£104.57M	0.34	-£278.26K	-£3.94	N/A
Novacyt	£20.03M	1.34	-£36.80M	-£32.00	N/A

BATM Advanced Communications has a beta of 0.754, indicating that its share price is 25% less volatile than the broader market. Comparatively, Novacyt has a beta of 1.112, indicating that its share price is 11% more volatile than the broader market.

14.3% of BATM Advanced Communications shares are held by institutional investors. Comparatively, 10.7% of Novacyt shares are held by institutional investors. 31.0% of BATM Advanced Communications shares are held by company insiders. Comparatively, 0.4% of Novacyt shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BATM Advanced Communications has a net margin of -15.91% compared to Novacyt's net margin of -103.08%. BATM Advanced Communications' return on equity of -25.90% beat Novacyt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BATM Advanced Communications	-15.91%	-25.90%	0.58%
Novacyt	-103.08%	-96.44%	-27.98%

Summary

BATM Advanced Communications beats Novacyt on 9 of the 13 factors compared between the two stocks.

Get Novacyt News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NCYT vs. The Competition

Export

Metric	Novacyt	Healthcare Equipment & Supplies Industry	Healthcare Sector	LON Exchange
Market Cap	£26.83M	£5.45B	£7.14B	£2.81B
Dividend Yield	N/A	1.80%	2.53%	6.18%
P/E Ratio	-1.16	24.90	275.68	366.16
Price / Sales	1.34	67.46	658.18	89,437.04
Price / Cash	0.58	32.43	77.60	27.89
Price / Book	0.37	5.73	10.93	6.83
Net Income	-£36.80M	£152.68M	£3.51B	£5.89B
7 Day Performance	-15.91%	-1.71%	-2.01%	-0.73%
1 Month Performance	-15.91%	-4.81%	-6.15%	16.59%
1 Year Performance	-8.45%	1.08%	7.44%	23.09%

Novacyt Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NCYT Novacyt	N/A	GBX 37 -7.5%	N/A	-10.8%	£26.83M	£20.03M	N/A	120	News Coverage Earnings Report
EKF EKF Diagnostics	N/A	GBX 25.65 +2.6%	GBX 35 +36.5%	-19.3%	£109.82M	£51.35M	54.57	356	Gap Up
SPEC INSPECS Group	N/A	GBX 95 +1.6%	N/A	+107.2%	£103.72M	£193.23M	N/A	1,673
CREO Creo Medical Group	N/A	GBX 12.50 +2.0%	GBX 40 +220.0%	-17.7%	£60.73M	£6M	12.50	279	News Coverage Earnings Report
IUG Intelligent Ultrasound Group	N/A	N/A	N/A	N/A	£42.76M	£6.57M	N/A	65

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:NCYT) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novacyt (NCYT) Competitors

NCYT vs. EKF, SPEC, CREO, IUG, and BVC

How does Novacyt compare to EKF Diagnostics?

Summary

How does Novacyt compare to INSPECS Group?

Summary

How does Novacyt compare to Creo Medical Group?

Summary

How does Novacyt compare to Intelligent Ultrasound Group?

Summary

How does Novacyt compare to BATM Advanced Communications?

Summary

Media Sentiment Over Time

NCYT vs. The Competition

Novacyt Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novacyt (NCYT) Competitors

NCYT vs. EKF, SPEC, CREO, IUG, and BVC

How does Novacyt compare to EKF Diagnostics?

Which has better earnings and valuation, NCYT or EKF?

Which has more risk and volatility, NCYT or EKF?

Is NCYT or EKF more profitable?

Do analysts recommend NCYT or EKF?

Does the media favor NCYT or EKF?

Do insiders and institutionals believe in NCYT or EKF?

Summary

How does Novacyt compare to INSPECS Group?

Which has higher valuation & earnings, SPEC or NCYT?

Is SPEC or NCYT more profitable?

Do institutionals & insiders believe in SPEC or NCYT?

Does the media refer more to SPEC or NCYT?

Which has more risk & volatility, SPEC or NCYT?

Summary

How does Novacyt compare to Creo Medical Group?

Is NCYT or CREO more profitable?

Does the media prefer NCYT or CREO?

Do insiders and institutionals believe in NCYT or CREO?

Which has more volatility & risk, NCYT or CREO?

Which has preferable earnings and valuation, NCYT or CREO?

Summary

How does Novacyt compare to Intelligent Ultrasound Group?

Does the media prefer IUG or NCYT?

Which has more risk and volatility, IUG or NCYT?

Is IUG or NCYT more profitable?

Do institutionals & insiders hold more shares of IUG or NCYT?

Which has higher valuation & earnings, IUG or NCYT?

Summary

How does Novacyt compare to BATM Advanced Communications?

Does the media refer more to BVC or NCYT?

Which has better earnings & valuation, BVC or NCYT?

Which has more risk and volatility, BVC or NCYT?

Do institutionals and insiders have more ownership in BVC or NCYT?

Is BVC or NCYT more profitable?

Summary

Media Sentiment Over Time

NCYT vs. The Competition

Novacyt Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools